Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091986 · ClinicalTrials.gov registry record · Phase 3
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
NCT02091986 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 882 participants.
The verdict
NCT02091986, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
Study Summary
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to \<12 Years with Asthma during 12 weeks.
Interventions
- DRUG Symbicort pMDI
- OTHER Budesonide pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02091986
The ClinicalTrials.gov registry entry for NCT02091986 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 882 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Symbicort pMDI is the first listed.
NCT02091986 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02091986 about?
NCT02091986 is a clinical study titled "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg". The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to \<12 Years with Asthma during 12 weeks.
What is the current status of trial NCT02091986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2014-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02091986?
The interventions under investigation include: Symbicort pMDI (DRUG), Budesonide pMDI (OTHER).
Who is sponsoring clinical trial NCT02091986?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.